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ABSTRACT
IL-17 activates NF-kB and induces expression of proinflammatory genes. IL-17 drives disease in autoimmune conditions, and anti–IL-
17 Abs have shown impressive success in the clinic. Although produced by lymphocytes, IL-17 predominantly signals in fibroblasts
and epithelial cells. IL-17–driven inflammation is kept in check by negative feedback signaling molecules, including the ubiquitin
editing enzyme A20, whose gene TNFAIP3 is linked to autoimmune disease susceptibility. The A20 binding inhibitor of NF-kB
activation 1 (ABIN-1) is an A20-binding protein encoded by the TNIP1 gene, which is also linked to autoimmune disease susceptibility
including psoriasis. Accordingly, we hypothesized that ABIN-1 might play a role in negatively regulating IL-17 signaling activity.
Indeed, ABIN-1 enhanced both tonic and IL-17–dependent NF-kB signaling in IL-17–responsive fibroblast cells. Interestingly, the
inhibitory activities of ABIN-1 on IL-17 signaling were independent of A20. ABIN-1 is a known NF-kB target gene, and we found that
IL-17–induced activation of NF-kB led to enhanced ABIN-1 mRNA expression and promoter activity. Surprisingly, however, the ABIN-
1 protein was inducibly degraded following IL-17 signaling in a proteasome-dependent manner. Thus, ABIN-1, acting independently
of A20, restricts both baseline and IL-17–induced inflammatory gene expression. We conclude that IL-17–induced signals lead to
degradation of ABIN-1, thereby releasing a constitutive cellular brake on NF-kB activation. ImmunoHorizons, 2017, 1: 133–141.
INTRODUCTION
Interleukin 17A (IL-17) is produced by lymphocytes and acts on
tissue ﬁbroblasts and epithelial cells to activate inﬂammatory gene
expression. IL-17 is required to clear extracellular pathogens,
particularly fungi such asCandida albicans (1). However, excessive
IL-17 signaling is associated with autoimmune diseases such as
psoriasis, psoriatic arthritis, and ankylosing spondylitis, among
others. IL-17 blocking therapies have shown considerable eﬃcacy
in treating psoriatic patients, and are being evaluated for various
other conditions (2).
The mechanisms of signaling mediated by IL-17 are incom-
pletely deﬁned. Produced by Th17 cells and a variety of innate
lymphocyte subsets, IL-17 and its receptor belong to a subclass of
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cytokines with distinct structural properties comparedwith other
cytokine superfamilies. After IL-17 binds to its receptor, numerous
signaling intermediates are engaged to transduce downstream
signaling. One key early event is activation of the Act1 and TRAF6
E3 ubiquitin ligases. These in turn lead to degradation of the IkB
inhibitor and nuclear translocation of the NF-kB transcription
factor (3–5). Consequently, genes with promoters containing
NF-kB–binding elements are upregulated by IL-17 stimulation,
with IL-6 (Il6) and Lipocalin-2 (Lcn2) being prototypical IL-17
target genes (6).
To date, the mechanisms that constrain the IL-17 pathway are
not well understood, which is an important issue in light of the
autoimmune potential of this cytokine. Recently, we showed that
the ubiquitin editing enzyme A20 inhibits IL-17 signaling by de-
ubiquitinating TRAF6 and thereby limiting NF-kB and MAPK
activation (7). Moreover, IL-17 upregulates A20 expression,
establishing a negative feedback loop that restricts IL-17–driven
inﬂammation. A20 is encoded by TNFAIP3, a genetic locus
frequently associated with human autoimmune diseases. In
seeking to understand how IL-17 controls autoimmunity, we
evaluated other genetic loci connected to IL-17-driven autoim-
mune conditions. TheA20-binding inhibitor of NF-kB activation 1
(ABIN-1) is an A20-binding protein coded by the TNIP1 gene.
ABIN-1 single nucleotide polymorphisms are associated with
psoriasis in human genome–wide association analyses (8–11).
Additionally, mice with keratinocytes lacking ABIN-1 are more
sensitive to imiquimod-induced dermatitis, a model of psoriasis
(12). Because IL-17 signaling is associated with psoriasis and
inhibitedbyA20,wehypothesized that ABIN-1might also serve as
a downstream inhibitor of the IL-17 signaling pathway.
In this study, we demonstrate that ABIN-1 constitutively
restricts the basal expression of IL-17 target genes such as Il6 in
ﬁbroblasts and stromal cells. ABIN-1 also negatively regulates IL-
17–induced production of Il6, Lcn2, and other NF-kB–dependent
genes, although not all IL-17–inducible genes are aﬀected.
Although ABIN-1 is known to interact with A20, we found that
A20 is not needed for ABIN-1–mediated inhibition of IL-17
signaling.Additionally, IL-17 inducedexpressionofABIN-1 (Tnip1)
mRNA, driven through its proximal promoter. Surprisingly,
however, ABIN-1 protein levels were reduced following IL-17
signaling, an event thatwasmediated by proteasomal degradation.
Thus, IL-17 signaling serves to release the ABIN-1–controlled
brake on inﬂammation, revealing a new regulatory circuit in the
IL-17 inﬂammatory pathway.
MATERIALS AND METHODS
Abs and reagents
Abs. AbsusedwereABIN-1 (SC134660; SantaCruzBiotechnology,
SantaCruz,CAor4664;Cell Signaling, Beverly,MA), IkBa (SC371;
Santa Cruz Biotechnology), a-tubulin (ab40742; Abcam, Cam-
bridge, MA), and b-actin (ab49900; Abcam). Secondary Abs were
from Thermo Fisher Scientiﬁc. Inhibitors were MG132 (474790-
100UG, 20 mM), staurosporine (569396, 100 nM), and inhibitor of
NF-kB kinase (IKK) inhibitor VII (401486-1MG, 10 mM; EMD
MilliporeSigma, Billerica, MA).
HEK293T cells were cultured in DMEM and ST2 cells and
murine embryonic ﬁbroblasts (MEFs) were cultured in a-MEM
(Sigma-Aldrich, StLouis,MO)containing 10%FBSwith L-glutamine
and antibiotics (Invitrogen). Transfections were performed with
Fugene HD (Promega, Madison, WI) or Lipojet (SignaGen,
Rockville, MD). Plasmids expressing ABIN-1, the ABIN-1 pro-
moter, and the Lcn2 promoter were previously described (13–15).
Luciferase assays were performed as described (7, 14). Small
interfering RNAs (siRNAs) were from Dharmacon (GE, Lafayette,
CO): Tnip1 (ABIN-1) (L-047652-01), Tnfaip3 (A20) (L-058907-02),
andnontargetingmock (D-001810-10-20). siRNA transfectionswere
performed 48 h prior to stimulation. In all cases eﬃciency of
knockdown was conﬁrmed by quantitative PCR (qPCR).
RNA isolation, qPCR, and ELISA
RNAwasextractedusingRNAeasyKits (74106;Qiagen) andcDNA
was made to perform qPCR. Primers were from Qiagen: Tnip1
(QT00149009), Tnfaip3 (QT00134064), Gapdh (QT01658692), Il6
(QT00098875), Lcn2 (QT00113407), Cxcl1 (QT00115647), Ccl20
(QT02326394), and Nfkbiz (QT00143934). Relative gene expres-
sionwas normalized toGapdh. ELISA kits were from eBioscience.
Immunoprecipitation and immunoblotting
Cellswere lysedon ice for 20min in lysis buﬀer (1%NP40, 150mM
NaCl, 50 mM Tris pH 8.0, 2 mM NaF) supplemented with 1 mM
Na2VO4, 50mMPMSF, 10mMb-glycerophosphate disodium salt,
and a protease inhibitormixture (Sigma-Millipore). Sampleswere
boiled in running buﬀer and immunoblotted. Band intensity was
analyzed using AlphaView SA Version 3.4.0 (Protein Simple, San
Jose, CA).
Statistics
To assess signiﬁcance, we used the Student t test, ANOVAwith post
hoc Tukey analysis, or linear regression. A p value , 0.05 was
considered signiﬁcant. Error bars reﬂect the mean 6 SEM of
replicateswithin individual experiments or pooleddata, as indicated
in the ﬁgure legends. All experiments were repeated at least twice.
RESULTS
ABIN-1 inhibits both basal and IL-17–induced
gene expression
To delineate the role of ABIN-1 in IL-17–mediated signaling, we
assessed IL-17 signaling in immortalized MEFs lacking ABIN-1
(16). Cells were treated with IL-17 over a 24 h period, and IL-6 in
culture supernatants was assessed by ELISA. At baseline,
ABIN-12/2 ﬁbroblasts secreted signiﬁcantly more IL-6 than
ABIN-1+/+ cells (Fig. 1A). Similarly, ABIN-12/2 cells treated with
IL-17 expressed more IL-6 than IL-17–stimulated ABIN-1+/+ cells.
Consistent with these ﬁndings, elevated expression of Il6 mRNA
was observed inABIN-12/2MEFs, both at baseline and after IL-17
stimulation (Fig. 1B). These results indicate that ABIN-1 restricts
https://doi.org/10.4049/immunohorizons.1700035
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FIGURE 1. ABIN-1 inhibits tonic and IL-17–dependent gene expression in mesenchymal cells.
(A) Kinetics of ABIN-1–mediated inhibition of IL-6 expression. ABIN-1+/+ or ABIN-12/2 fibroblasts were treated with IL-17 (200 ng/ml) for the
indicated times, and IL-6 in conditioned supernatants was measured by ELISA. Data are representative of three experiments. Data are presented as
mean values; *p, 0.05, two-way ANOVA with Sidak multiple comparisons test analyzing all groups. (B) ABIN-1 restricts Il6 basal expression. ABIN-1+/+
or ABIN-12/2 fibroblasts were treated with IL-17 for 3 h, and Il6 mRNA was assessed by qPCR and normalized to Gapdh. *p , 0.05, two-way ANOVA
with Sidak multiple comparisons test compared with untreated ABIN-1+/+ sample. (C) ABIN-1 reconstitution inhibits Il6 expression. (Continued)
https://doi.org/10.4049/immunohorizons.1700035
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both tonic and IL-17–dependent IL-6 expression. To conﬁrm that
ABIN-1 limits IL-6 expression levels and to rule out the possibility
that this eﬀect was restricted to a particularMEF line, ABIN-12/2
ﬁbroblasts were reconstituted with ABIN-1 by transfection. Cells
were then stimulated with IL-17 for 3 h and Il6 mRNA was
measured by qPCR. Consistent with its role as an inhibitor of
inﬂammatory signaling, reconstitution with ABIN-1 decreased Il6
production compared with cells transfected with a control vector
(Fig. 1C).
To verify the inhibitory activity of ABIN-1 in another setting,
we silenced ABIN-1 with siRNA in ST2 cells, a mouse bone
marrow stromal cell line that responds robustly to IL-17 (Fig. 1D)
(14). Indeed, knockdown of ABIN-1 led to increased expression of
IL-6 at baseline and following IL-17 stimulation (Fig. 1E). Il6
mRNA was similarly enhanced upon ABIN-1 knockdown, as was
expression of other IL-17 target genes including Lcn2 and Cxcl1
(Fig. 1F). However, not all IL-17–induced genes were impacted by
ABIN-1 deﬁciency; for example,Ccl20 andNfkbiz (encoding IkBz)
are IL-17 target genes that are restricted by A20 but not by ABIN-1
(Fig. 1F) (7). Together, these results demonstrate that ABIN-1 is a
negative regulatorof tonic andIL-17–inducedsignaling, selectively
controlling expression of a subset of IL-17 target genes.
ABIN-1 inhibits IL-17R signaling independently of A20
Because ABIN-1 was identiﬁed based on its ability to bind A20, we
asked whether ABIN-1–mediated inhibition of IL-17R signaling is
dependent on A20 (17). Accordingly, we knocked down ABIN-1
in A202/2 ﬁbroblasts by RNA silencing. As shown, reduced
expression of ABIN-1 led to enhanced Il6 and Lcn2 expression,
both at baseline and after IL-17 stimulation, similar to wild-type
MEFs and ST2 cells (Fig. 2A). In an independent approach to
address theroleofA20 inABIN-1activity,wecotransfectedA202/2
MEFs with ABIN-1 together with a luciferase reporter driven by
the Lcn2 promoter (18). Cells were stimulated with IL-17 for 6 h
and Luc activity assessed. As we previously reported, A202/2
ﬁbroblasts showedonly amodest responsiveness to IL-17, probably
because baselineNF-kB is constitutively high in the absence ofA20
(7). Nonetheless, Lcn2-promoter activity was markedly reduced
upon transfection of ABIN-1 or A20, conﬁrming that A20 is
dispensable for the inhibitory function of ABIN-1 (Fig. 2B). As a
third method to assess the role of A20, we transfected ST2 cells
with the Lcn2 luciferase reporter with either a full-length ABIN-1
or a truncated mutant lacking the A20-binding domain (but
retaining the NF-kB–inhibitory C-terminal domain) (Fig. 2C) (15).
In response to IL-17, both the full-length and truncated forms of
ABIN-1 inhibited IL-17–dependent Lcn2-promoter activation (Fig.
2C). Collectively, these ﬁndings demonstrate that ABIN-1 sup-
presses IL-17 activity and tonic inﬂammatory signaling indepen-
dently of A20.
ABIN-1 regulates IL-17--activated NF-kB signaling
ABIN-1 is known to inhibit NF-kB in the context of TNF-a
stimulation, and the above results suggested ABIN-1 suppressed
NF-kB–dependent genes in the IL-17 pathway as well (19–22). An
early step in the canonical NF-kB signaling pathway is phosphor-
ylation of the inhibitor IkBa, which leads to its degradation by the
proteasome, releasing NF-kB for nuclear translocation.Moreover,
the gene encoding IkBa is induced in an NF-kB–dependent
manner, establishing a negative feedback loop (23). To determine
whether ABIN-1 targets NF-kB in the IL-17 signaling cascade, we
assessed IL-17–dependent IkBa degradation in ABIN-12/2
ﬁbroblasts. In ABIN-12/2 cells transfected with a control empty
vector (EV), IkBa was degraded within 15 min following IL-17
stimulation and remained at low levels for as long as 60 min
poststimulation (Fig. 3A, lanes 5–8). In contrast, in ABIN-12/2
ﬁbroblasts reconstituted with ABIN-1, IkBawas restored to basal
levels by 60 min (Fig. 3A, lane 4). Therefore, there is prolonged
activationofNF-kBsignalingwhenABIN-1 isdeﬁcient.Thesedata
indicate that ABIN-1 inhibits IL-17–dependent NF-kB signaling
upstream of IkBa degradation.
To conﬁrm that ABIN-1 inhibits NF-kB, we knocked down
ABIN-1 in ST2 cells and evaluated NF-kB activation by IL-17. In
ST2 cells transfected with a control (mock) siRNA IkBa returned
to normal levels 60 min after IL-17 stimulation (Fig. 3B, lane 4).
However, when ABIN-1 was reduced, cells deﬁcient in this
molecule could not re-establish pretreatment levels of IkBa (Fig.
3B, lane 8). These data suggest that ABIN-1 is required to inhibit
IL-17–dependent NF-kB signaling upstream of IkBa.
To further deﬁne the mechanism by which ABIN-1 inhibits
IL-17 signaling, we measured IL-17–dependent Lcn2 promoter
activation in ST2 cells transfected with full-length ABIN-1 or a
mutant with a nonfunctional ubiquitin binding domain (UBAN)
(15). Whereas the full-length ABIN-1 inhibited IL-17–dependent
Lcn2 promoter activation, the UBANmutant did not impair basal
ABIN-12/2 fibroblasts were transiently transfected with an ABIN-1–expressing plasmid or EV. After 24 h, cells were treated with IL-17 for 3 h and Il6 was
assessed by qPCR. Data are presented as the fold-induction of Il6 in IL-17–stimulated cells compared with unstimulated samples. Data are normalized
to untreated cells transfected with the same plasmid. *p , 0.05, two-way ANOVA with Sidak multiple comparisons test compared with ABIN-12/2
untreated. (D) ABIN-1 knockdown efficiency. ST2 cells were transfected with siRNA targeting ABIN-1 or a scrambled siRNA (mock) control. ABIN-1
(Tnip1) expression was assessed by qPCR (left) and ABIN-1 protein by immunoblotting (right). *p , 0.05, two-way ANOVA with Sidak multiple
comparisons test compared with mock, unstimulated cells. (E) ABIN-1 silencing enhances tonic and IL-17–induced IL-6 production. ST2 cells were
transfected with the indicated siRNAs. After 48h cells were stimulated with IL-17 for 3 h, and secreted IL-6 was assessed by ELISA. *p , 0.05, two-way
ANOVA with Sidak multiple comparisons test compared with mock unstimulated cells. (F) ABIN-1 silencing enhances tonic and IL-17–induced
expression of some but not all IL-17 target genes. ST2 cells from (E) were analyzed for the expression of the indicated genes by qPCR. *p , 0.05, two-
way ANOVA with Sidak multiple comparisons test compared with mock unstimulated cells. (B–F) Data are representative of three independent
experiments.
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signaling and partially inhibited IL-17 signaling (Fig. 3C). This
may suggest that ABIN-1 restricts NF-kB activity by diﬀerent
mechanisms, with the IL-17–dependent activity being UBAN
dependent. Thus, ABIN-1 is a negative regulator of NF-kB
activation in response to IL-17 signaling. Additionally, the
UBANofABIN-1 is required to inhibit both tonicandIL-17–induced
signaling.
IL-17 signaling differentially regulates ABIN-1 mRNA
and protein
IL-17 induces several known signaling inhibitors to establish
feedback signaling loops, including IkBa, A20, and Regnase-1/
MCP1-induced protein 1, all of which are regulated by NF-kB.
ABIN-1 is also a known NF-kB target gene, raising the possibility
that IL-17 might also induce its expression (24). Accordingly, we
measured ABIN-1 mRNA by qPCR following IL-17 stimulation. A
linear regression model showed that IL-17 signiﬁcantly, albeit
modestly, induced ABIN-1 (Tnip1) mRNA over time, resulting in
;2-fold increased levels over 2 h (Fig. 4A). This induction was
NF-kB dependent, as expression was blocked in the presence of
an IKK inhibitor (Fig. 4B). Moreover, IL-17 induction of ABIN-1
occurred at the level of the promoter, as veriﬁed in ST2 cells
transfectedwith the full-length (6 kb) ABIN-1 proximal promoter
(13, 25) (Supplemental Fig. 1A, 1B). Transfection of CCAAT
enhancer binding protein (C/EBPb) or NF-kB p65, transcription
factors regulated by IL-17, was also suﬃcient to drive ABIN-1
promoter activation (Supplemental Fig. 1C). These data support
the hypothesis that IL-17 induces ABIN-1 mRNA through its
proximal promoter via C/EBPb and NF-kB.
Inprobing regulationof theABIN-1protein,wewere surprised
to see that expression of ABIN-1 was reproducibly decreased
following IL-17 stimulation comparedwith the unstimulated (time
FIGURE 2. ABIN-1 inhibits IL-17 signaling independently of A20.
(A) ABIN-1 knockdown in A202/2 fibroblasts maintains enhanced Il6 and Lcn2 expression. A202/2 MEFs were transfected with ABIN-1 or mock
siRNA and Il6 and Lcn2 expression were assessed by qPCR. (B) IL-17–induced Lcn2-promoter activation is inhibited in A202/2 cells by ABIN-1.
A202/2 MEFs were transfected with the Lcn2-promoter (18) together with plasmids expressing ABIN-1 or A20. After 24 h, cells were treated with
IL-17 for 6 h and luciferase activity was measured. (C) An ABIN-1 mutant lacking the A20 binding domain inhibits IL-17–dependent Lcn2-promoter
activation. Left: Schematic representation of ABIN-1 protein (FL, full length) and the 444-647 mutant lacking the A20 binding site. Right: ST2 cells
were transfected with the Lcn2-promoter reporter together with FL or 444-647 forms of ABIN-1. Then 24 h posttransfection, cells were stimulated
with IL-17 for 6 h and luciferase activity measured. *p , 0.05, two-way ANOVA with Tukey multiple comparisons test compared with cells
transfected with E.V. and treated with IL-17 in (C) and (B), or with cells treated with mock siRNA and stimulated with IL-17 (A). Data are representative
of three independent experiments.
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zero) time point (Fig. 4C). A similar trend was seen in MEFs
(Supplemental Fig. 2A, 2B). To determine whether the reduced
ABIN-1 levels were due to proteasomal degradation, cells were
treated with IL-17 in the presence of the proteasome inhibitor
MG132. Blocking proteasome function prevented ABIN-1 protein
degradation after IL-17 treatment, which was most notable at the
early (15 min) time point (Fig. 4D). These data indicate that, even
though the ABIN-1 promoter is activated by IL-17, ABIN-1 is
inducibly degraded in an IL-17–dependent manner. This un-
expected ﬁnding suggests that IL-17 signaling releases a brake in
inﬂammation that is normally controlled by ABIN-1.
DISCUSSION
Exacerbated IL-17R signaling is associated with psoriasis and
other autoimmune conditions (2, 26–28). Accordingly, it is not
surprising that there are negative regulators that act on the IL-17
signaling cascade to prevent the overexuberant inﬂammatory
responses that underlie tissue pathology. Notably, many of these
inhibitory pathways converge on NF-kB activation (3). The
development of autoimmunity is associated with polymorphisms
ingenes that inﬂuenceNF-kBactivity, suchasTNFAIP3 (encoding
A20), NFKBIA (encoding IkBa), and TNIP1 (encoding ABIN-1)
(29, 30). In prior work, we found that A20 is part of a feedback
loop that restricts IL-17–mediated TRAF6 ubiquitination,
which is required for NF-kB andMAPK activation; this ﬁnding
prompted the present analyses of the A20-binding protein
ABIN-1 (7). Because of its A20-binding capacity, it is frequently
assumed that ABIN-1’s functions involve A20 (17, 31, 32).
Indeed, ABIN-1 coexpression with A20 was shown to induce
destabilization of the IKK complex and inhibition of NF-kB
signaling in a lower chordate model organism (33). Similarly,
ABIN-1 cooperates with A20 to inhibit antiviral signaling or
TNF-regulated NF-kB signaling (20, 34). In contrast, our data
show that ABIN-1 acts independently of A20 in the context of
IL-17R signal transduction (Fig. 2).
Most of what is known about ABIN-1 comes from studies of
TNF-a or LPS. ABIN-1 controls signaling by several reported
mechanisms, including (1) inhibiting IKK complex activity by
binding to NEMO (IKKg) (20); (2) inhibiting ubiquitination
and degradation of p105 to block p50 production in the
noncanonical NF-kB pathway (21); and (3) by associating with
and thus blocking TNF receptor adaptors such as RIP and
TRAF2 (17). ABIN-1 requires its UBAN for its function, as a
D485N mutation within the UBAN suppressed binding to K63
or linear polyubiquitin chains. In vivo, this mutation caused
systemic inﬂammation and autoimmunity (35). This phenotype
FIGURE 3. ABIN-1 inhibits IL-17–dependent NF-kB activation.
(A) ABIN-12/2 fibroblasts exhibit prolonged activation of IL-17–dependent NF-kB signaling. ABIN-12/2 MEFs were transfected with ABIN-1 or EV,
rested for 24 h, and stimulated with IL-17 (200 ng/ml) for the indicated times. IkBa degradation was assessed by immunoblotting of total cell lysates.
Right: Band intensities were assessed by densitometry. Results are representative of three independent experiments. (B) ABIN-1 knockdown
prolongs activation of IL-17–induced NF-kB. ST2 cells were transfected with ABIN-1 or mock siRNAs for 48 h and treated with IL-17 for the
indicated times. Whole cell lysates were immunoblotted for IkBa. Right: Band intensities were assessed by densitometry. Results are representative
of three independent experiments. (C) The UBAN contributes to the inhibitory function of ABIN-1. ST2 cells were transfected with the Lcn2-
promoter reporter together with and ABIN-1 or mutant lacking the UBAN domain (DF485/486NA). After 24 h, cells were treated with IL-17 for 6 h
and luciferase activity was measured. Data are representative of three experiments. *p , 0.05, two-way ANOVA with Tukey multiple comparisons test.
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was considered to be an LPS-mediated response, but involvement
of IL-17 was not explored. In this study, we demonstrate that a
similar mutation in the UBAN eliminates ABIN-1–mediated in-
hibition of tonic and IL-17–dependent signaling (Fig. 3), raising the
possibility that some eﬀects of the D485N mutation could be
ascribed to IL-17.
An unexpected ﬁnding in this study was the dichotomy by
which IL-17 regulates ABIN-1 mRNA versus protein. We found
consistently IL-17 triggersmodest upregulation of ABIN-1mRNA.
Consistent with its mRNA induction, IL-17 activates the ABIN-1
proximal promoter (Fig. 4). NF-kB regulates the gene promoter
activity of ABIN-1, inducing its mRNA as a late expression gene
compared with the A20 expression after TNF-a stimulation (13,
24). These data thus suggested that ABIN-1 is part of a similar
negative feedback loop, analogous to other IL-17 signaling
inhibitors such as A20 and MCP1-induced protein 1/Regnase-1
(7, 36). Indeed, in HeLa cells NF-kB was found to induce
expression of ABIN-1, whereas ABIN-1 in turn repressed NF-kB
activity (13).However, the impact of IL-17 onABIN-1 protein levels
contrasted strikingly and unexpectedly with its transcriptional
activation, because the net eﬀect of IL-17 was to downregulate
ABIN-1 protein levels (Fig. 4). Interestingly, the phenomenon of
ABIN-1 degradation after an inﬂammatory stimulus is evident in
the published literature, although to our knowledge it has never
been remarked upon. For example, ABIN-1 levels decreased after
TLR and TNF-a stimulation of bone marrow–derived macro-
phages with approximately the same kinetics as we observed with
IL-17 signaling (35). Additionally, studies in human psoriatic skin
lesion biopsies showed increased ABIN-1 mRNA but decreased
protein, indicating that this phenomenon occurs in a settingwhere
both IL-17 and ABIN-1 are known to be clinically relevant (11).
Mice in which ABIN-1 is conditionally deleted in keratinocytes
develop more severe skin inﬂammation than control mice after
imiquimod-induceddermatitis,which is associatedwith increased
expressionof IL-17 target genessuchasCxcl1 andCcl20 (12).These
ﬁndings therefore conﬁrm the physiologic connection between
ABIN-1 and IL-17.
How do we reconcile the idea that IL-17 (and other stimuli)
induces ABIN-1 transcription yet triggers protein loss? We
speculate that the answer lies in the persistence of the stimulus
and the kinetics of activation. In the early phase of inﬂammatory
signals, ABIN-1 protein is degraded within 1–2 h, which serves to
enhance inﬂammation. Simultaneously,ABIN-1mRNAexpression
is upregulated by NF-kB and C/EBPb, at least somewhat
replenishing the pool of translated ABIN-1. In washout experi-
ments,we found thatABIN-1protein levels return tobaseline;4h
after IL-17 withdrawal (data not shown), thus returning the cell
to a constitutively inhibited state. However, when IL-17 signals
FIGURE 4. IL-17 signaling upregulates ABIN-1 mRNA but downregulates protein.
(A) ABIN-1 (Tnip1) mRNA is upregulated by IL-17. ST2 cells were stimulated with IL-17 for the indicated times, and Tnip1 was analyzed by qPCR.
Relative mRNA expression was assessed by linear regression modeling (p = 0.0085). Data are pooled from five independent experiments. (B) NF-kB
regulates ABIN-1 mRNA. ST2 cells were pretreated with 10 mM IKK inhibitor VII for 30 min or DMSO and treated with IL-17 for 3 h. mRNA was
analyzed by qPCR. Data are representative of three experiments. *p , 0.05 two-way ANOVA with Tukey multiple comparisons test compared to
untreated sample. (C) ABIN-1 protein is downregulated upon IL-17 signaling. Left: ST2 cells were treated with IL-17 (200 ng/ml) and whole cell
lysates were analyzed by immunoblotting. Lanes 7–8: cells were transfected with mock or ABIN-1 siRNA to confirm the identity of ABIN-1 band.
Right: Relative protein band intensities were compared with the unstimulated time point (time zero) and analyzed by linear regression. Data are
pooled from six independent experiments. (D) ABIN-1 is degraded by the proteasome. Left: ST2 cells were pretreated with MG-132 for 30 min or
DMSO and treated with IL-17 for the indicated times. Whole cell lysates were analyzed by immunoblotting. Right: Relative protein band intensities
were compared with time of stimulation and analyzed by linear regression. Data were pooled from four independent experiments.
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continuously, ABIN-1 degradation was maintained. Thus, the
inhibitory activity ofABIN1 is compromisedwhile there is ongoing
stimulation. This might explain the observation that in patients
withpsoriasis there is elevatedmRNAbut decreasedprotein levels
for ABIN-1 (11). Psoriasis is linked to several inﬂammatory
cytokines, with a predominant role for IL-17A signaling, based in
part on the success of anti–IL-17A and anti–IL-17RA biologic
drugs (26, 37–39). Therefore, the idea that ABIN-1 is both a
tonic inhibitor of inﬂammation and a negative regulator of IL-17
signaling ﬁts well with our data and with ﬁndings in preclinical
mouse models and human studies (10–12).
There are other examples of inhibitors that are downregulated
by the signals that they regulate. In the case of IL-17R signaling,
the proximal adaptor Act1 is degraded following phosphorylation
to temper all downstream signaling events (40), and IkBa is
degraded followingphosphorylation tounmask theNF-kBnuclear
import signal (41). IL-17 is just one of multiple immune eﬀectors
that can initiate ABIN-1 degradation and presumably thereby
enhance inﬂammation. Moreover, IL-17 signals synergistically
with many of these cytokines, particularly TNF-a (3, 42). Thus,
ABIN-1 appears to regulate signaling at the intersection of these
inﬂammatory stimuli, namely, the IKK complex.
These data have possible implications for therapeutic inter-
ventions. We show that ABIN-1 degradation is at least partially
mediated by the proteasome, with no apparent contribution of
caspases or the lysosome (data not shown). Therapeutics targeting
the proteasome are used for cancer (43), and might be useful in
diseases where ABIN-1 is implicated, i.e., those where TNIP1
single nucleotide polymorphisms are found. Another consider-
ation is settings where overproduction of ABIN-1 activators such
as IL-17 or TNF-a (e.g., autoimmunity, microbiome dysbiosis)
might lead to underexpression of ABIN-1 and hence chronic
inﬂammation andassociatedharmful sequelae.Clearly,morework
needs to be done to dissect the role of this important but enigmatic
molecule in the context of inﬂammation.
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